查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1417246

嗜中性白血球低下症治療市場報告：2030 年趨勢、預測與競爭分析

Neutropenia Treatment Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 - page report | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

嗜中性白血球低下症治療的趨勢與預測

全球嗜中性白血球低下症治療市場的未來看起來充滿希望，醫院藥房、零售藥房和線上藥房市場充滿機會。預計到 2030 年，全球嗜中性白血球低下症治療市場將達到約 203 億美元，2024 年至 2030 年複合年成長率為 6.0%。這個市場的主要驅動力是癌症診斷的迅速增加，產業透過研發努力開拓嗜中性白血球低下症治療方法，以及類風濕性關節炎、狼瘡和克隆氏症等自體免疫疾病，以及感染疾病發生頻率的增加，例如類風濕性關節炎、紅斑性狼瘡和克隆氏症。如敗血症、結核病和肝炎。

嗜中性白血球低下症治療市場洞察

Lucintel 預計集落刺激因子將在預測期內達到最高成長。

醫院藥房將繼續成為該市場的最大部分。

預計亞太地區在預測期內將出現最高成長。

常問問題

Q.1嗜中性白血球低下症治療藥物的市場規模有多大？

A1. 到 2030 年，全球嗜中性白血球低下症治療市場預計將達到 203 億美元。

Q.2嗜中性白血球低下症治療市場的成長預測是多少？

A2. 2024年至2030年，全球嗜中性白血球低下症治療市場預計將以6.0%的複合年成長率成長。

Q.3 影響嗜中性白血球低下症治療市場成長的關鍵因素有哪些：

A3. 該市場的主要驅動力是癌症診斷的快速增加、業界不斷致力於透過研究和開發嗜中性白血球低下症治療方法，以及類風濕性關節炎、狼瘡和克隆氏症等自體免疫疾病，以及感染疾病。

Q4.市場的主要細分市場是：

A4.嗜中性白血球低下症治療市場前景看好，醫院藥局、零售藥局和網路藥局市場都有機會。

Q5.市場的主要企業是：

A5. 主要的嗜中性白血球低下症治療公司如下。

  • Teva Pharmaceutical Industries
  • Novartis
  • Mylan
  • Spectrum Pharmaceuticals
  • Beyondspring
  • Coherus Biosciences
  • Kyowa Kirin
  • Cellerant Therapeutics
  • Pfizer
  • Amgen

Q6.未來最大的細分市場是什麼？

A6.Lucintel 預計集落刺激因子在預測期內將出現最高成長。

Q7. 未來五年預計哪些地區的市場成長最大？

A7. 預計亞太地區在預測期內將出現最高成長。

Q8. 可以客製化報告嗎？

A8. 是的，Lucintel 提供 10% 的客製化服務，無需額外付費。

目錄

第1章執行摘要

第2章嗜中性白血球低下症治療市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球嗜中性白血球低下症治療市場趨勢（2018-2023）與預測（2024-2030）
  • 按治療分類的全球嗜中性白血球低下症治療市場
    • 集落刺激因子
    • 抗生素
    • 抗真菌藥物
    • 抗病毒藥物
  • 按分銷管道分類的全球嗜中性白血球低下症治療市場
    • 醫院藥房
    • 零售藥房
    • 網路藥房

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球嗜中性白血球低下症症治療市場（按地區）
  • 嗜中性白血球低下症治療市場
  • 歐洲嗜中性白血球低下症症治療市場
  • 亞太地區中性嗜中性白血球低下症治療市場
  • 其他地區嗜中性白血球低下症治療市場

第5章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 全球嗜中性白血球低下症治療市場按治療的成長機會
    • 全球嗜中性白血球低下症治療市場成長機會（按分銷管道）
    • 全球嗜中性白血球低下症治療市場按地區成長機會
  • 全球嗜中性白血球低下症治療市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 擴大全球嗜中性白血球低下症治療市場的產能
    • 全球嗜中性白血球低下症治療市場的合併、收購和合資企業
    • 認證和許可

第7章主要企業概況

  • Teva Pharmaceutical Industries
  • Novartis
  • Mylan
  • Spectrum Pharmaceuticals
  • Beyondspring
  • Coherus Biosciences
  • Kyowa Kirin
  • Cellerant Therapeutics
  • Pfizer
  • Amgen
簡介目錄

Neutropenia Treatment Trends and Forecast

The ffuture of the global neutropenia treatment market looks promising with opportunities in the hospital pharmacies, retail pharmacies, and online pharmacies markets. The global neutropenia treatment market is expected to reach an estimated $20.30 billion by 2030 with a CAGR of 6.0% from 2024 to 2030. The major drivers for this market are surge in cancer diagnoses, growing industry commitment to pioneering neutropenia therapies through research and development, and increasing frequency of autoimmune illnesses including rheumatoid arthritis, lupus, and Crohn's disease, as well as infections like sepsis, TB, and hepatitis.

A more than 150-page report is developed to help in your business decisions.

Neutropenia Treatment by Segment

The study includes a forecast for the global neutropenia treatment by treatment, distribution channel, and region.

Neutropenia Treatment Market by Treatment [Shipment Analysis by Value from 2018 to 2030]:

  • Colony-Stimulating Factor
  • Antibiotics
  • Antifungals
  • Antivirals

Neutropenia Treatment Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Onlne Pharmacies

Neutropenia Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Neutropenia Treatment Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies neutropenia treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the neutropenia treatment companies profiled in this report include-

  • Teva Pharmaceutical Industries
  • Novartis
  • Mylan
  • Spectrum Pharmaceuticals
  • Beyondspring
  • Coherus Biosciences
  • Kyowa Kirin
  • Cellerant Therapeutics
  • Pfizer
  • Amgen

Neutropenia Treatment Market Insights

Lucintel forecasts that colony-stimulating factor is expected to witness highest growth over the forecast period.

Within this market, hospital pharmacies will remain the largest segment.

APAC is expected to witness highest growth over the forecast period.

Features of the Global Neutropenia Treatment Market

Market Size Estimates: Neutropenia treatment market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Neutropenia treatment market size by treatment, distribution channel, and region in terms of value ($B).

Regional Analysis: Neutropenia treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different treatment, distribution channel, and regions for the neutropenia treatment market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the neutropenia treatment market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the neutropenia treatment market size?

Answer: The global neutropenia treatment market is expected to reach an estimated $20.30 billion by 2030.

Q.2 What is the growth forecast for neutropenia treatment market?

Answer: The global neutropenia treatment market is expected to grow with a CAGR of 6.0% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the neutropenia treatment market?

Answer: The major drivers for this market are surge in cancer diagnoses, growing industry commitment to pioneering neutropenia therapies through research and development, and increasing frequency of autoimmune illnesses including rheumatoid arthritis, lupus, and Crohn's disease, as well as infections like sepsis, TB, and hepatitis.

Q4. What are the major segments for neutropenia treatment market?

Answer: The future of the neutropenia treatment market looks promising with opportunities in the hospital pharmacies, retail pharmacies, and online pharmacies markets.

Q5. Who are the key neutropenia treatment market companies?

Answer: Some of the key neutropenia treatment companies are as follows.

  • Teva Pharmaceutical Industries
  • Novartis
  • Mylan
  • Spectrum Pharmaceuticals
  • Beyondspring
  • Coherus Biosciences
  • Kyowa Kirin
  • Cellerant Therapeutics
  • Pfizer
  • Amgen

Q6. Which neutropenia treatment market segment will be the largest in future?

Answer: Lucintel forecasts that colony-stimulating factor is expected to witness highest growth over the forecast period.

Q7. In neutropenia treatment market, which region is expected to be the largest in next 5 years?

Answer: APAC is expected to witness highest growth over the forecast period.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the neutropenia treatment market by treatment (colony-stimulating factor, antibiotics, antifungals, and antivirals), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Neutropenia Treatment Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Neutropenia Treatment Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Neutropenia Treatment Market by Treatment
    • 3.3.1: Colony-Stimulating Factor
    • 3.3.2: Antibiotics
    • 3.3.3: Antifungals
    • 3.3.4: Antivirals
  • 3.4: Global Neutropenia Treatment Market by Distribution Channel
    • 3.4.1: Hospital Pharmacies
    • 3.4.2: Retail Pharmacies
    • 3.4.3: Onlne Pharmacies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Neutropenia Treatment Market by Region
  • 4.2: North American Neutropenia Treatment Market
    • 4.2.2: North American Neutropenia Treatment Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Onlne Pharmacies
  • 4.3: European Neutropenia Treatment Market
    • 4.3.1: European Neutropenia Treatment Market by Treatment: Colony-Stimulating Factor, Antibiotics, Antifungals, and Antivirals
    • 4.3.2: European Neutropenia Treatment Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Onlne Pharmacies
  • 4.4: APAC Neutropenia Treatment Market
    • 4.4.1: APAC Neutropenia Treatment Market by Treatment: Colony-Stimulating Factor, Antibiotics, Antifungals, and Antivirals
    • 4.4.2: APAC Neutropenia Treatment Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Onlne Pharmacies
  • 4.5: ROW Neutropenia Treatment Market
    • 4.5.1: ROW Neutropenia Treatment Market by Treatment: Colony-Stimulating Factor, Antibiotics, Antifungals, and Antivirals
    • 4.5.2: ROW Neutropenia Treatment Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Onlne Pharmacies

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Neutropenia Treatment Market by Treatment
    • 6.1.2: Growth Opportunities for the Global Neutropenia Treatment Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Neutropenia Treatment Market by Region
  • 6.2: Emerging Trends in the Global Neutropenia Treatment Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Neutropenia Treatment Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Neutropenia Treatment Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Teva Pharmaceutical Industries
  • 7.2: Novartis
  • 7.3: Mylan
  • 7.4: Spectrum Pharmaceuticals
  • 7.5: Beyondspring
  • 7.6: Coherus Biosciences
  • 7.7: Kyowa Kirin
  • 7.8: Cellerant Therapeutics
  • 7.9: Pfizer
  • 7.10: Amgen